China Blood Product Industry Report, 2016-2019
  • Mar.2016
  • Hard Copy
  • USD $2,800
  • Pages:150
  • Single User License
    (PDF Unprintable)       
  • USD $2,650
  • Code: ZYM075
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $4,000
  • Hard Copy + Single User License
  • USD $3,000

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources are the key to the development of Chinese blood product enterprises. Amid the industrial prosperity and favorable policies, China had more than 190 plasma collection stations with the production-use plasma volume of 4, 700 tons and the total lot release volume jumped by 3.36 million bottles year on year to 55.76 million bottles in 2015.

Given stringent requirements on new domestic plasma stations, Shanghai RAAS, China Biologic Products (Shandong Taibang and Guizhou Taibang), Hualan Biological Engineering, Tiantan Biological (including Chengdu Rongsheng) and Yuanda Shuyang which boast abundant capital, powerful R&D strength and rich plasma station resources have become the top five companies in China blood product industry, contributing 61.9% to China’s production-use plasma volume in 2015.

From the point of view of the product structure, human albumin is still the largest type of blood products in China, but its supply has slowed down with a lower contribution 58.8% to China’s total blood product lot release volume in 2015. In recent years, the rising lot release volume of Chinese human albumin is mainly attributed to ample supply of imported products. In 2011-2015, the lot release volume of human albumin imported by China grew at a CAGR of 23.7%, accounting for as much as 55.6% of the total. China's top four human albumin import enterprises --- Behring, Baxter, Grifols and Octapharma seized 50.7% of the total lot release volume in 2015.

China's second largest type of blood products -- human immunoglobulin (ph4) for intravenous injection saw its lot release volume jump by 31.5% year on year to 9.4 million bottles (2.5g / bottle) and its share increase to 16.9% in 2015. Over the same period, tetanus human immunoglobulin, hepatitis B immune globulin and other immune globulin products and coagulation factor products witnessed growth in lot release volume except human rabies immunoglobulin whose lot release volume declined slightly.

The research and development of human blood coagulation factor VIII, human prothrombin complex and other small products in rigid demand has made the most remarkable progress in recent years. Concerning human blood coagulation factor VIII, Shanghai Xinxing had been approved to launched its human blood coagulation factor VIII, Shenzhen Weiguang had entered the new drug registration stage, Guangdong Shuanglin Bio-Pharmacy had embarked on trial production, Jiangxi Boya Bio-Pharmaceutical had gone into clinical phase III (the industrialization is expected in H2 2016), Wuhan Zhongyuan Ruide had obtained clinical approval and Harbin Pacific Biopharmaceutical had applied for clinical approval by the end of 2015.

In order to possess and effectively use plasma raw materials, enterprises are more willing to cooperate mutually in addition to acquisition. In August 2015, China Biologic Products and Xinjiang Deyuan signed a strategic cooperation agreement, under which the former should purchase at least 120/180/200 tons of plasma from the latter per year in the next three years. In 2015, Hebei Da’an Pharmaceutical and Guangdong Weilun actively planned to cooperate on the allocation of plasma fraction II + III, namely the former (it only produces human albumin now) should allocate partial plasma fraction II + III to Guangdong Weilun for the production of immunoglobulin products.

China Blood Product Industry Report, 2016-2019 focuses on the followings:
20120114.gifMarket characteristics, operating environments, status quo, etc. of China blood product industry;
20120114.gifSupply and demand, competition pattern, import and export, development forecast, etc. of China blood product industry;
20120114.gifSupply and demand, competition pattern, etc. of 8 blood product segments, including human albumin, human immunoglobulin (pH4) for intravenous injection, blood coagulation factor and tetanus human immunoglobulin;
20120114.gifOperation, blood product business and prospects of 13 major Chinese blood product companies.

血液制品  英文_副本.png

1. Overview of Blood Product Industry
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features

2. Overview of China Blood Product Industry
2.1 Market Size 
2.2 Status Quo 
2.3 Supply and Demand 
2.3.1 Supply 
2.3.2 Demand 
2.4 Competition 
2.5 Operating Environment
2.5.1 International
2.5.2 Policy 
2.5.3 Domestic Biopharmaceutical Market
2.6 Import and Export

3. Blood Product Market Segments in China
3.1 Human Albumin 
3.1.1 Supply and Demand 
3.1.2 Competition Pattern
3.1.3 Prospects 
3.2 Human Immunoglobulin (pH4) for Intravenous Injection 
3.2.1 Supply and Demand 
3.2.2 Competition Pattern
3.3 Blood Coagulation Factor VIII 
3.3.1 Supply and Demand 
3.3.2 Competition Pattern
3.3.3 Prospects
3.4 Hepatitis B Immunoglobulin 
3.4.1 Supply and Demand 
3.4.2 Competition Pattern
3.5 Human Immunoglobulin 
3.5.1 Supply and Demand 
3.5.2 Competition Pattern
3.6 Human Prothrombin Complex 
3.6.1 Supply and Demand 
3.6.2 Competition Pattern
3.7 Tetanus Immunoglobulin 
3.7.1 Supply and Demand 
3.7.2 Competition Pattern
3.8 Human Rabies Immunoglobulin  
3.8.1 Supply and Demand 
3.8.2 Competition Pattern

4. Major Chinese Manufacturers
4.1 China Biologic Products Inc. (NASDAQ: CBPO)
4.1.1 Profile 
4.1.2 Operation 
4.1.3 Revenue Structure  
4.1.4 Customers and Suppliers 
4.1.5 R&D and Investment
4.1.6 Shandong Taibang Biological Products Co., Ltd.
4.1.7 Guizhou Taibang Biological Products Co., Ltd.
4.1.8 Xi'an Huitian Blood Products Co., Ltd.
4.1.9 Outlook and Prospects
4.2 Hualan Biological Engineering Inc. (002007.SZ)
4.2.1 Profile 
4.2.2 Operation 
4.2.3 Revenue Structure 
4.2.4 Gross Margin 
4.2.5 Customers and Suppliers  
4.2.6 R&D and Investment
4.2.7 Blood Products 
4.2.8 Outlook and Prospects
4.3 Shanghai RAAS Blood Products Co., Ltd. (002252.SZ)
4.3.1 Profile 
4.3.2 Operation 
4.3.3 Revenue Structure 
4.3.4 Gross Margin 
4.3.5 Customers and Suppliers 
4.3.6 R&D and Investment
4.3.7 Outlook and Prospects
4.4 Beijing Tiantan Biological Products Co., Ltd. (TIANTANBIO, 600161.SH)
4.4.1 Profile 
4.4.2 Operation 
4.4.3 Revenue Structure 
4.4.4 Customers and Suppliers 
4.4.5 Gross Margin 
4.4.6 R&D and Investment 
4.4.7 Blood Products (Chengdu Rongsheng Pharmaceutical Co., Ltd.)
4.4.8 Outlook and Prospects
4.5 Zhenxing Biopharmaceutical and Chemical Co., Ltd. (000403.SZ)
4.5.1 Profile 
4.5.2 Operation 
4.5.3 Revenue Structure 
4.5.4 Gross Margin 
4.5.5 Customers and Suppliers 
4.5.6 R&D and Investment 
4.5.7 Blood Products (Guangdong Shuanglin Bio-Pharmacy Co., Ltd.)
4.5.8 Outlook and Prospects
4.6 Jiangxi Boya Bio-Pharmaceutical Co., Ltd. (300294.SZ)
4.6.1 Profile 
4.6.2 Operation 
4.6.3 Revenue Structure 
4.6.4 Gross Margin 
4.6.5 Customers and Suppliers 
4.6.6 R&D and Investment 
4.6.7 Outlook and Prospects
4.7 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. 
4.7.1 Profile 
4.7.2 Blood Products 
4.8 Shanghai Institute of Biological Products Co., Ltd. 
4.8.1 Profile 
4.8.2 Blood Products 
4.9 Shanxi Kangbao Biological Product Co., Ltd. 
4.9.1 Profile 
4.9.2 Blood Products 
4.10 Green Cross 
4.10.1 Profile  
4.10.2 Blood Products 
4.11 Humanwell Healthcare Group Co., Ltd. (600079.SH)
4.11.1 Profile 
4.11.2 Operation 
4.11.3 Blood Products (Wuhan Zhongyuan Ruide Biological Product Co., Ltd.)
4.12 Walvax Biotechnology Co, Ltd. (300142.SZ)
4.12.1 Profile 
4.12.2 Operation 
4.12.3 Blood Products (Hebei Da’an Pharmaceutical Co., Ltd. and Guangdong Weilun Biological Pharmaceutical Co., Ltd.)
4.13 Shenzhen Weiguang Biological Products Co., Ltd.
4.13.1 Profile 
4.13.2 Operation 
4.13.3 Revenue Structure 
4.13.4 Gross Margin 
4.13.5 Customers and Suppliers 
4.13.6 R&D and Investment 
4.13.7 Outlook and Prospects

5. Summary and Forecast
5.1 Company Analysis
5.2 Growth Prediction
Basic Components of Blood
Plasma Protein Separation Procedure
Classification and Function of Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products
Comparison between Domestic and Foreign Recombinant Blood Products in Types
Blood Product Industry Chain
Time Consumption of Plasma Collection and Separation Process 
Comparison between Blood Product Enterprises and Chemical & Pharmaceutical Enterprises in Operating Costs and Expenses 
Prices of Some Blood Products in China, 2014
Blood Product Market Size in China, 2003-2015
Lot Release Volume of Blood Products in China (by Product), 2009-2015
Blood Product Structure in China (by Lot Release Volume), 2009-2015
Per Capita Frequency of Plasma Donation and Plasma Collection in China vs. the Occident
Plasma Collections in China vs. USA
Production-use Plasma Volume in China, 2008-2015
Number of Plasma Collection Stations in China, 2008-2015
Geographical Distribution of Plasma Station Resources in China by the End of 2015
Mainstream Blood Products with Medical Insurance Coverage in China
Per Capita Consumption of Blood Products in China vs. Developed Countries
Plasma Station Distribution, Production-use Plasma Volume and Blood Product Revenue of Major Blood Product Enterprises in China, 2014
Plasma Station Distribution, Production-use Plasma Volume and Blood Product Revenue of Major Blood Product Enterprises in China, 2015
Comparison of Chinese Blood Product Manufacturing Enterprises in Product Line
Competition Pattern of Global Blood Product Enterprises, 2013
Product Structure of Global Blood Products
Blood Products Available in Overseas Market
Global Blood Product Manufacturers
Main Policies on Chinese Blood Products
Policies on Maximum Retail Price of Drugs in China, 2014-2015
Lot Release Volume of Imported Human Albumin in China, 2008-2015
Average Human Albumin Purchase Price of Sample Hospitals in China, 2005-2014
Proportion of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2015
Market Share of Major Human Albumin Manufacturers in China (by Lot Release Volume), 2008-2015
Consumption of Human Immunoglobulin (pH4) for Intravenous Injection per 1,000 Persons by Country, 2013 (g/1,000 persons)
Lot Release Volume and Growth Rate of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2007-2015
Price of Human Immunoglobulin (pH4) for Intravenous Injection in China vs. Other Countries
Average Purchase Price of Human Immunoglobulin (pH4) for Intravenous Injection of Sample Hospitals in China, 2005-2014
Market Share of Major Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2007-2015
Lot Release Volume and Growth Rate of Blood Coagulation Factor VIII in China, 2008-2015
Market Share of Major Human Blood Coagulation Factor VIII Manufacturers in China (by Lot Release Volume), 2008-2015
Comparison between Human Blood Coagulation Factor VIII and Recombinant Blood Coagulation Factor VIII
Per Capita Consumption of Recombinant VIII Factor and Plasma VIII Factor in Major Countries (IU/Person)
Lot Release Volume and Growth Rate of Hepatitis B Immunoglobulin in China, 2009-2015
Market Share of Major Hepatitis B Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2015
Prices of Human Immunoglobulin in China by Dosage, 2014
Lot Release Volume and Growth Rate of Human Immunoglobulin in China, 2008-2015
Market Share of Major Human Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2015
Lot Release Volume and Growth Rate of Human Prothrombin Complex in China, 2008-2015
Market Share of Major Human Prothrombin Complex Manufacturers in China (by Lot Release Volume), 2008-2015
Lot Release Volume and Growth Rate of Tetanus Immunoglobulin in China, 2008-2015
Market Share of Major Tetanus Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2015
Rabies Incidents and Death Rate in China, 2008-2014
Lot Release Volume and Growth Rate of Human Rabies Immunoglobulin in China, 2008-2015
Market Share of Major Human Rabies Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2015
Equity Structure of China Biologic Products by the End of 2014
Distribution of Blood Products Manufacturing Bases and Plasma Stations of CBPO, 2015
Revenue and Operating Income of CBPO, 2008-2015
Gross Margin of CBPO, 2011-2015
Revenue Breakdown of CBPO (by Product), 2011-2015
Revenue Structure of CBPO (by Product), 2010-2015
CBPO’s Revenue from Top 5 Customers and % of Total Revenue, 2008-2014
R&D Costs and % of Total Revenue of CBPO, 2010-2015
Lot Release Volume of Blood Products of Shandong Taibang Biological Products, 2008-2015
Lot Release Volume of Blood Products of Guiyang Qianfeng Biological Products, 2008-2015
Lot Release Volume of Blood Products of Xi'an Huitian Blood Products, 2008-2014
Revenue and Operating Income of CBPO, 2014-2019E
Revenue and Operating Income of Hualan Biological Engineering Inc., 2008-2015
Revenue of Hualan Biological Engineering Inc. (by Sector), 2008-2015
Gross Margin of Hualan Biological Engineering Inc. (by Product), 2008-2015
Hualan Biological Engineering Inc.’s Revenue from Top 5 Customers and % of Total Revenue, 2007-2014
Hualan Biological Engineering Inc.’s Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2014
Name List and Procurement Contribution of Hualan Biological Engineering Inc.’s Top 5 Suppliers, 2014
R&D Costs and % of Total Revenue of Hualan Biological Engineering Inc., 2008-2015
Types and Specifications of Blood Products of Hualan Biological Engineering Inc.
Distribution of Plasma Collection Stations of Hualan Biological Engineering Inc. by the End of 2015
Lot Release Volume of Blood Products of Hualan Biological Engineering Inc., 2008-2015
Revenue and Gross Margin of Blood Products of Hualan Biological Engineering Inc., 2008-2015
Revenue and Gross Margin of Blood Products of Hualan Biological Engineering Inc. (by Product), 2008-2015
Revenue and Operating Income of Hualan Biological Engineering Inc., 2014-2019E
Shanghai RAAS’s Subsidiaries and Their Operation, H1 2015 (RMB mln)
Distribution of Plasma Stations of Shanghai RAAS by the End of 2015
Revenue and Operating Income of Shanghai RAAS, 2008-2015
Lot Release Volume of Blood Products of Shanghai RAAS, 2008-2015
Lot Release Volume of Blood Products of Tonrol Bio-Pharmaceutical, 2008-2015
Operating Revenue of Shanghai RAAS (by Product), 2008-2015
Revenue of Shanghai RAAS (by Region), 2008-2015
Gross Margin of Shanghai RAAS (by Product), 2008-2015
Shanghai RAAS’s Revenue from Top 5 Customers and % of Total Revenue, 2008-2015
Shanghai RAAS’s Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2014
R&D Costs and % of Total Revenue of Shanghai RAAS, 2008-2015
Revenue and Operating Income of Shanghai RAAS, 2014-2019E
TIANTANBIO’s Subsidiaries and Their Revenue and Income, H1 2015 (RMB mln)
Revenue and Operating Income of TIANTANBIO, 2008-2015
Revenue of TIANTANBIO (by Sector), 2008-2015 
Revenue of TIANTANBIO (by Region), 2008-2015 
TIANTANBIO’s Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2014
TIANTANBIO’s Revenue from Top 5 Customers and % of Total Revenue, 2008-2014
Gross Margin of TIANTANBIO (by Sector), 2008-2015
R&D Costs and % of Total Revenue of TIANTANBIO, 2009-2015
Distribution of Plasma Collection Stations of TIANTANBIO by the End of 2015
Revenue and Gross Margin of Blood Products of TIANTANBIO, 2008-2015
Lot Release Volume of Blood Products of RonSen and TIANTANBIO, 2008-2015
Revenue and Operating Income of TIANTANBIO, 2014-2019E
Revenue and Operating Income of Zhenxing Biopharmaceutical and Chemical, 2008-2015
Operating Revenue of Zhenxing Biopharmaceutical and Chemical (by Product), 2009-2015
Gross Margin of Zhenxing Biopharmaceutical and Chemical (by Product), 2009-2015
Zhenxing Biopharmaceutical and Chemical’s Revenue from Top 5 Customers and % of Total Revenue, 2009-2014
Name List and Revenue Contribution of Zhenxing Biopharmaceutical and Chemical’s Top 5 Customers, 2014
Zhenxing Biopharmaceutical and Chemical’s Procurement from Top 5 Suppliers and % of Total Procurement, 2014
R&D Costs and % of Total Revenue of Zhenxing Biopharmaceutical and Chemical, 2009-2015
Production-use Plasma Volume of Shuanglin Bio-Pharmacy, 2010-2015
Distribution of Plasma Collection Stations of Shuanglin Bio-Pharmacy by the End of 2015
Lot Release Volume of Blood Products of Shuanglin Bio-Pharmacy, 2008-2015
Revenue and Gross Margin of Blood Products of Zhenxing Biopharmaceutical and Chemical, 2009-2015
Revenue and Operating Income of Zhenxing Biopharmaceutical and Chemical, 2014-2019E
Distribution of Single Plasma Collection Stations of Jiangxi Boya Bio-Pharmaceutical by the End of 2015
Plasma Collection Volume of Jiangxi Boya Bio-Pharmaceutical, 2008-2015
Revenue and Operating Income of Jiangxi Boya Bio-Pharmaceutical, 2008-2015
Revenue of Jiangxi Boya Bio-Pharmaceutical (by Product), 2009-2015
Lot Release Volume of Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2011-2014
Operating Revenue of Jiangxi Boya Bio-Pharmaceutical (by Region), 2009-2014
Gross Margin of Jiangxi Boya Bio-Pharmaceutical (by Product), 2009-2015
Jiangxi Boya Bio-Pharmaceutical’s Revenue from Top 5 Customers and % of Total Revenue, 2009-2015
Jiangxi Boya Bio-Pharmaceutical’s Procurement from Top 5 Suppliers and % of Total Procurement, 2009-2015
R&D Costs and % of Total Revenue of Jiangxi Boya Bio-Pharmaceutical, 2009-2015
Products under Research and Progress of Jiangxi Boya Bio-Pharmaceutical as of Oct. 2015
Revenue and Operating Income of Jiangxi Boya Bio-Pharmaceutical, 2014-2019E
Distribution of Plasma Stations of Sichuan Yuanda Shuyang Pharmaceutical by the End of 2015
Lot Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical, 2008-2015
Lot Release Volume of Blood Products of Shanghai Institute of Biological Products, 2008-2015
Distribution of Plasma Stations of Shanghai Institute of Biological Products by the End of 2015
Distribution of Plasma Stations of Shanxi Kangbao Biological Product by the End of 2015
Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2008-2015
Distribution of Plasma Stations of Green Cross China by the End of 2015
Lot Release Volume of Blood Products of Green Cross China, 2008-2015
Revenue and Operating Income of Humanwell Healthcare, 2009-2015
Lot Release Volume of Blood Products of Wuhan Zhongyuan Ruide Biological Product, 2008-2015
Production Industry Layout of Walvax Biotechnology
Revenue and Operating Income of Walvax Biotechnology, 2009-2015
Revenue of Walvax Biotechnology (by Product), 2009-2015
Distribution of Single Plasma Collection Stations of Shenzhen Weiguang Biological Products by the End of 2015
Plasma Collection Volume and Production-use Plasma Volume of Shenzhen Weiguang Biological Products, 2012-2015
Revenue and Operating Income of Shenzhen Weiguang Biological Products, 2012-2015
Capacity, Production and Sales Volume of Shenzhen Weiguang Biological Products (by Product), 2012-2015
Revenue Breakdown of Shenzhen Weiguang Biological Products (by Product), 2012-2015 (RMB mln)
Revenue Structure of Shenzhen Weiguang Biological Products (by Product), 2012-2015 (RMB mln)
Gross Margin of Shenzhen Weiguang Biological Products (by Product), 2012-2015
Name List and Revenue Contribution of Shenzhen Weiguang Biological Products’ Top 5 Customers, 2012-2015
Name List and Procurement Contribution of Shenzhen Weiguang Biological Products’ Top 5 Suppliers, 2012-2015
R&D Costs and % of Total Revenue of Shenzhen Weiguang Biological Products, 2012-2015
Some Products under Research and Progress of Shenzhen Weiguang Biological Products by the End of 2015
Fundraising Projects of Shenzhen Weiguang Biological Products
Revenue and Operating Income of Shenzhen Weiguang Biological Products, 2014-2019E
Number of Plasma Stations of Major Blood Product Enterprises in China as of Dec. 2015
Production-use Plasma Volume of Major Blood Product Enterprises in China, 2014-2015
Blood Product Revenue of Major Blood Product Enterprises in China, 2011-2015
Major M&A Events of Blood Product Industry in China, 2008-2015
Market Size of Blood Products in China, 2014-2019E
Gross Margin of Major Blood Product Enterprises in China, 2011-2015

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号